<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598360</url>
  </required_header>
  <id_info>
    <org_study_id>EA2/113/08</org_study_id>
    <nct_id>NCT04598360</nct_id>
  </id_info>
  <brief_title>Release of Epoxyeicosatrienoic Acids From Erythrocytes During the Use of Extracorporeal Procedures (Heart-lung Machine)</brief_title>
  <official_title>A Lipidomics Study: Release of Epoxyeicosatrienoic Acids From Erythrocytes During the Use of Extracorporeal Procedures (Heart-lung Machine)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypotension with potentially serious consequences for organ perfusion is a common&#xD;
      complication in extracorporeal procedures such as heart-lung-machine. The exact reasons for&#xD;
      this are still insufficiently clarified. Probably periinterventional vasorelaxant released&#xD;
      substances play a crucial role in these procedures. These substances could be due to contact&#xD;
      of blood cells with the Membrane in the HLM arise. In this project the hypothesis will be&#xD;
      checked, if EETs / DHETs are released by Erythrocytes during this extracorporeal procedure&#xD;
      and thus act as potential candidate products for the result of hypotonic phases during usage&#xD;
      of heart-lung-machine.&#xD;
&#xD;
      We will determine differences in RBC fatty acids profiling in patients before and after&#xD;
      heart-lung-machine intervention. RBC fatty acids profiling will be achieved by using targeted&#xD;
      HPLC-MS mass spectrometry.&#xD;
&#xD;
      It is believed that during HLM there is an increase in EETs / DHETs in the serum and in the&#xD;
      erythrocytes. It is believed that shear forces play an important role in the release of&#xD;
      erythrocyte EETs / DHETs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of variation of relative quantities of erythrocyte fatty-acid parameters related to its dynamic during HLM, using LC-MS / MS.</measure>
    <time_frame>4-5months</time_frame>
    <description>EETs / DHETs will be analyzed in the erythrocytes and serum of the recovered blood samples.&#xD;
The determination will made in cooperation with a Berliner Biotech company. This involves liquid chromatography with MS coupling (LC-MS / MS) used. The data analysis is carried out by means of suitable statistical methods to perform erythrocyte fatty-acid status profiling.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Fatty Acid Metabolism</condition>
  <condition>Erythrocytes</condition>
  <condition>Lipidomics</condition>
  <condition>Heart-Lung-Machine</condition>
  <arm_group>
    <arm_group_label>Experimental: Erythrocyte Fatty-Acid Status</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erythrocyte Fatty-Acid Status Profiling of cardiac surgery patients are studied before and during heart-lung-machine procedure using LC-MS / MS</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Heart-Lung-Machine</intervention_name>
    <description>blood sample before and during a single Heart-Lung-Machine procedure</description>
    <arm_group_label>Experimental: Erythrocyte Fatty-Acid Status</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are undergoing an operation with the aid of the heart-lung machine for&#xD;
             cardiac surgery&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Ability to consent&#xD;
&#xD;
          -  There is a written consent of the study participant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        •none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Gollasch</last_name>
    <phone>(030) 4593 2000</phone>
    <email>benjamin.gollasch@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maik Gollasch</last_name>
    <email>maik.gollasch@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité University Experimental &amp; Clinical Research Center</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin Gollasch, Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Benjamin Gollasch</investigator_full_name>
    <investigator_title>Benjamin Gollasch</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

